Pinealon / EDRa three-letter peptide with a big preclinical story and a thin human one
Pinealon is a tiny three-amino-acid research peptide (Glu-Asp-Arg, "EDR") studied mostly for protecting brain cells from oxidative stress and for cognitive-aging research. The evidence is early and experimental — strong in cell and animal studies, but with only sparse, low-certainty human data from a single Russian research program. It should not be treated as an approved memory, Alzheimer's, longevity, or sleep treatment.
Pinealon / EDR is a synthetic tripeptide bioregulator with preclinical data suggesting ROS suppression, altered ERK1/2 timing, anti-necrotic effects, and possible neuroplasticity support in amyloid and metabolic-stress models. Human data are limited to small, low-certainty gerontology literature, with no validated PK, no approved indication, and no standardized dose. Nearly all research comes from one program (Khavinson, St. Petersburg).
EDR is an ultrashort acidic/arginine-containing tripeptide (C₁₅H₂₆N₆O₈; 418.4 Da) isolated from the polypeptide neuroprotective drug Cortexin, proposed to act through antioxidant-response modulation, ERK/MAPK timing shifts, cell-cycle effects, peptide–genome interactions, and dendritic-spine preservation under amyloid synaptotoxicity. Translational confidence is low: most claims are in-vitro, animal, or review-derived, and human dose-response/PK data are absent.
EDRGlu-Asp-Arg · 3-aa tripeptide
In vitroStrongest direct evidence is cell-based
1 programNearly all data from Khavinson group
No human PKNo t½ · no RCT · no approval
Status
Experimental · not FDA-approved · no US compounding pathway · WADA S0
Pinealon has an internally coherent preclinical story: in cells, it restricts reactive-oxygen-species accumulation and reduces necrotic death; in animal models, it supports cognition under stress and may preserve dendritic spines; mechanistically it's proposed to enter cells and modulate gene expression. But the human evidence is genuinely thin — a single small Russian gerontology study and a handful of open-label case series, with no human pharmacokinetics, no randomized controlled trials, and no regulatory approval anywhere. Nearly all of it comes from one research program. The honest framing: an experimental neuroprotective tripeptide with a promising mechanism and an unproven clinical reality.
🧠
Primary use case
Neuroprotection R&D
An experimental neuroprotective / cognitive-aging research peptide; strongest support is preclinical plus small Russian human gerontology data. Grade D.
Direct evidence is in-vitro ROS/viability work; the only human data is one small gerontology study — no large RCTs. Grade P → D.
💊
Dose
No validated dose
No validated therapeutic dose; modeling-only ranges extrapolated from the oral study, practice patterns, and animal µg/kg data. Grade D/P.
🇷🇺
Evidence source
Single program
Nearly all published Pinealon research originates from the Khavinson St. Petersburg program — limited independent Western replication. Grade D.
⚠️
Key risk
Unknown safety
Unknown human PK and long-term safety; impurity/immunogenicity risk if compounded; caution in pregnancy, CNS disease, malignancy. Grade D.
🏛️
Approval
Experimental
Not FDA- or EMA-approved; as a tissue-extract-derived bioregulator it has no recognized US compounding pathway. Grade D.
🏃
Anti-doping
WADA S0
As a non-approved substance, Pinealon falls under WADA S0 and is prohibited at all times in sport. Grade D.
02 · Mechanism of action
Mostly hypothesis and cell biology.
Pinealon's proposed mechanisms are a layered hypothesis: at the base, a reasonably direct in-vitro observation (it restricts ROS and reduces necrotic death in stressed cells, with altered ERK1/2 timing); above that, animal models of cognitive stress; and at the top, a more speculative gene-expression / peptide–genome story. The honest distinction this section keeps is that the ROS/ERK observations are Grade P (in vitro), the animal cognition is Grade C, and the "regulates gene expression in Alzheimer's pathways" claims are mechanistic hypotheses (Grade P) that need independent replication. None of it is established human pharmacology.
Grade P
🛡️
1 · Oxidative-stress suppression / ROS buffering
Pinealon may help cells resist oxidative stress in experimental neuronal and immune-cell models.
Clinical significance: The best direct evidence shows reduced ROS accumulation and lower necrotic cell death in cerebellar granule cells, neutrophils, and PC12 cells exposed to oxidative stressors — the page's firmest mechanistic anchor.
Molecular detail: The 2011 Rejuvenation Research study reported dose-dependent restriction of ROS accumulation and decreased propidium-iodide-positive necrotic death, linked with altered ERK1/2 timing and cell-cycle modification. Established in vitro; not clinically validated.
Grade P
⏱️
2 · ERK1/2 / MAPK timing & cell-cycle modulation
Pinealon may change how stressed cells move through survival and proliferation signals.
Clinical significance: ERK1/2 activation timing was delayed while cell-cycle behavior changed in vitro, suggesting more than simple antioxidant activity.
Molecular detail: ERK1/2 is part of MAPK signaling involved in proliferation, differentiation, stress responses, and survival; the delayed ERK1/2 activation is hypothesized to shift stress-response dynamics rather than acting only as a scavenger. Hypothesized translational pathway.
Pinealon is proposed to influence gene activity in brain-aging and neurodegeneration models.
Clinical significance: A 2020 Molecules review frames EDR as a peptide that may regulate gene expression and protein synthesis related to Alzheimer's-pathway biology — a striking claim that remains a hypothesis.
Molecular detail: Proposed mechanisms include peptide–DNA / peptide–chromatin interactions, altered transcription of neuroplasticity and stress-response genes, and downstream effects on neuronal-survival and synaptic-maintenance proteins. Mechanistic hypothesis; needs independent replication.
Grade P/C
🌿
4 · Dendritic-spine preservation under amyloid stress
Pinealon may help preserve synaptic structures in Alzheimer's-style experimental models.
Clinical significance: EDR and KED peptides were reported to prevent dendritic-spine loss in amyloid synaptotoxicity models, including in-vitro AD models and 5xFAD mouse literature.
Molecular detail: Proposed pathway: amyloid stress → synaptic Ca²⁺/calmodulin disruption and mushroom-spine loss → EDR/KED exposure → partial restoration or preservation of spine density and neuroplasticity pathways. Preclinical; not established as a human AD therapy.
In a rat model, Pinealon improved offspring cognitive outcomes after prenatal metabolic stress.
Clinical significance: Maternal hyperhomocysteinemia (methionine loading) was associated with offspring cognitive impairment; Pinealon improved cognitive function and neuronal resistance to oxidative stress in offspring.
Molecular detail: Proposed flow: prenatal hyperhomocysteinemia → oxidative neuronal vulnerability / cerebellar stress → Pinealon exposure → improved cognitive readouts and oxidative-stress resilience. Animal evidence; not transferable to human pregnancy or pediatric use.
Grade C
🥶
6 · Stress / hypoxia / neurochemical adaptation
Pinealon may influence behavioral and biochemical resilience under stress models.
Clinical significance: Aged-rat hypoxia/hypothermia studies reported behavioral and neurochemical changes — with Cortexin sometimes showing stronger effects than Pinealon on free-radical processes and caspase-3.
There is no validated dose for Pinealon. Human pharmacokinetics simply do not exist — no half-life, no Cmax, no bioavailability study has been published — so every figure below is a speculative modeling layer, not a protocol. The human study used oral dosing; animal work used intraperitoneal injection; the in-vitro work used nanomolar concentrations that cannot be converted to a human dose. The calculator below works in micrograms and validates arithmetic only. Read this section as "what numbers people model," not "what to take."
Thin human evidence · experimental · no approved dose
Pinealon's human evidence is limited to small, low-certainty gerontology literature; there is no FDA- or EMA-approved indication and no standardized clinical dose. As a tissue-extract-derived bioregulator it has no recognized US compounding pathway, and FDA's broader peptide-compounding concerns (impurity, immunogenicity, limited human testing) apply to unapproved peptides generally. The doses below are speculative research modeling — not a recommendation.
No human pharmacokinetics exist
No reliable human study has reported Pinealon's half-life, Cmax, Tmax, clearance, volume of distribution, or bioavailability for any route. Without a dose-response curve, any "target dose" is arbitrary. Selectable calculator doses are capped at 1000 µg to avoid implying a validated high-exposure band.
Oral — the human-study route
Where the (thin) human data comes from
Grade D
Evidence
A small Russian gerontology study used oral Pinealon/Vesugen in chronic polymorbidity and organic brain syndrome — details limited, not enough for approved dosing.
Starting (model)
1 mg/day oral for 3–5 days as a tolerance screen.
Ladder
1 → 2 → 3 mg/day, optional 5 mg/day cap; only if no CNS/sleep/GI/mood/BP effects.
Cycle
10–20 days modeled; 4–8 week washout (no PK/safety data to guide this).
Monitoring
Sleep, headache, mood, BP/HR, cognition log, GI symptoms — all unvalidated.
Avoid neurodegenerative-treatment claims; avoid in pregnancy/lactation; caution in active seizure disorder, psychiatric instability, uncontrolled hypertension. Grade D.
Absorption highly variable; contamination risk; no validated CNS-delivery data. Grade P.
IN note
Intranasal is hypothesis
Question
Answer
IN human study?
None located
Spray output validated?
No (must verify µg/spray)
Intraperitoneal — animal-model anchor
Preclinical route; NOT for human dosing
Grade C/P
Basis
Used in preclinical AD-model peptide research; not a clinical route.
Anchor
A related KED peptide was used at 400 µg/kg IP in a 5xFAD mouse study; EDR/KED studies inform mechanistic comparison, not human dose conversion.
Do not translate IP animal dose directly to human injection. Grade C/P.
Animal anchor
Why IP doesn't convert
Issue
Detail
Route
IP (mouse) ≠ human SC/oral
Conversion
No human PK to scale from
In vitro — cell-culture exposure
Where the direct evidence actually lives
Grade P
Basis
Direct Pinealon evidence includes in-vitro ROS/cell-viability studies.
Concentration anchor
~100 nM Pinealon prevented oxidant-induced ROS accumulation in experimental conditions — use only as an in-vitro anchor.
In-vitro nM concentrations cannot be converted into a human dose without PK/PD data. No clinical translation. Grade P.
In-vitro anchor
Cell-model parameters
Readout
Observation
ROS accumulation
Dose-dependent restriction
Necrotic death (PI)
Decreased
ERK1/2 timing
Delayed
L2 · Reconstitution math (research only)
Reconstitution & Dose Calculator
This calculator validates injectable concentration and draw-volume arithmetic only (working unit: µg). It is not a prescribing tool — Pinealon has no validated human dose, no human PK, and no approval. Targets are capped at 1000 µg to avoid implying a validated high band. The human study used oral dosing; injectable use is practice-pattern.
Concentration
—
Draw volume
—
Units (U-100)
—
Doses/vial
—
Basis
—
04 · Combinations
Stacks built on practice, not trials.
Every Pinealon combination is a conceptual pairing from the bioregulator/nootropic practice world — none has been tested in a controlled trial, so all are Grade D/P. The most common framing pairs it with its sibling Epitalon, but they have genuinely different proposed mechanisms (Pinealon neuroprotective/EDR; Epitalon pineal/telomerase/circadian), so the page's job is to stop readers from treating them as equivalent. The hard constraint is the same as for any experimental CNS-active peptide: avoid stacking in pregnancy/lactation, active malignancy, uncontrolled seizure disorder, active mania/psychosis, or competitive sport.
Pinealon + Epitalon / AEDG
Sibling bioregulators
Pinealon (EDR)Epitalon (AEDG)
Both are short bioregulator peptides, but Epitalon is pineal/telomerase/circadian-focused while Pinealon is neuroprotective/EDR-focused. Do not merge mechanisms or claim Pinealon is Epitalon-equivalent — they're siblings, not synonyms. Grade D/P.
Peptide
Focus
Pinealon (EDR)
Neuroprotection / ROS
Epitalon (AEDG)
Pineal / telomerase
Pinealon + Semax
Cognitive concept
PinealonSemax
A cognitive/neuroprotection stack concept; Semax has separate neuropeptide literature and an intranasal practice history. Additive CNS stimulation, headache, or irritability is unknown — no combination data. Grade D.
Element
Note
Semax
ACTH-fragment / BDNF claims
Combo
No trials
Pinealon + Selank
Stress / cognition concept
PinealonSelank
Positioned by practice pattern for stress/anxiety/cognition. Sedation-vs-stimulation effects may conflict, and there are no combination trials. A conceptual pairing only. Grade D.
A theoretical "neuro-oxidative-stress + mitochondrial resilience" stack. No validated combination safety; avoid in cancer/proliferative disorders without physician oversight given Pinealon's gene-expression claims. Grade P/D.
Layer
Target
Pinealon
Neuronal ROS
SS-31 / MOTS-c
Mitochondria
Hard-constraint clinical note — Avoid stacking Pinealon with other experimental CNS-active peptides in pregnancy/lactation, active malignancy, uncontrolled seizure disorder, active mania/psychosis, or competitive sport without anti-doping clearance. None of these combinations has any controlled human evidence — they are conceptual pairings from the bioregulator practice world, and the Epitalon pairing in particular must not be presented as if the two peptides are interchangeable.
05 · Safety & contraindications
"No reported problems" — mostly means "not studied".
Pinealon's apparent safety is largely the absence of data rather than the presence of reassuring data. There is no large controlled human safety database; the in-vitro studies show reduced necrotic death under oxidative stress, but that is a cell-survival readout, not human safety; and the single small gerontology study is far too limited for long-term safety conclusions. Layered on top are the standard risks of any unapproved injectable peptide — impurity, sterility, dosing error, immunogenicity. The theoretical risks follow from the mechanism itself: CNS-active effects (headache, sleep, mood), and uncertainty in malignancy given the gene-expression/cell-cycle claims.
Safety signals & risks
No large human safety databaseApparent tolerability reflects absence of study, not proven safety. Grade D.
In-vitro: reduced necrotic deathCells under oxidative stress showed less necrotic death — a survival readout, not human safety. Grade P.
CNS-active effects possibleHeadache, sleep disruption, mood change, dizziness are plausible given the CNS-active hypothesis. Grade D.
Unknown seizure-threshold effectsNo data on seizure threshold; caution in seizure disorders. Grade D.
Malignancy uncertaintyGene-expression / cell-cycle claims are mechanistic and not risk-characterized in cancer. Grade D.
Pregnancy / lactation: no dataNo fetal or infant-exposure safety data. Grade D.
Impurity / immunogenicity (injectable)Unapproved compounded/research peptides carry sterility, dosing-error, and immune-reaction risk. Grade D.
Single-program evidenceNearly all data is from one group with limited independent replication — a confidence limitation, not a documented harm. Grade D.
Practical safety framework
Absence of harm reports ≠ safety
The honest reading is that Pinealon hasn't been studied enough to characterize its safety. The bioregulator class and its parent compound Cortexin are often described as well-tolerated, but that's a class impression, not a Pinealon-specific controlled safety dataset — and it shouldn't be read as a green light.
The mechanism defines the theoretical risks
Because the proposed mechanism is CNS-active and touches gene expression and the cell cycle, the logical cautions are neuropsychiatric destabilization, seizure-threshold uncertainty, and malignancy uncertainty — none observed in a trial, but all reasonable contraindications until data exists.
Product quality is a concrete, present risk
With no approved product and no US compounding pathway, anything obtained is research-grade or gray-market. Sterility, identity, endotoxin, and impurity are real risks regardless of what the molecule itself does — often the most immediate hazard for an experimental injectable peptide.
The most honest one-line summary of Pinealon's evidence is: a coherent preclinical story, almost entirely from one research group, with one small human study and no RCTs. The direct in-vitro work (ROS suppression, ERK timing) is the firmest piece but is still cell-level (Grade P). Animal models add cognitive and dendritic-spine findings (Grade C). The human evidence is a single small gerontology study (Grade D) plus a few open-label case series. There is no human pharmacokinetics, no dose-ranging, no randomized placebo-controlled trial, and no independent Western replication. The page grades accordingly — there is no Grade A or B source here.
Cerebellar granule cells, neutrophils, PC12: ROS restriction, less necrotic death. Grade P.
Animal · 2012
Cognition ↑
Rat prenatal hyperhomocysteinemia offspring: improved cognition + oxidative resistance. Grade C.
Human RCT
None
No randomized placebo-controlled trial; no human PK. Grade D.
PIn vitro · ROS / ERK (key mechanism)
Khavinson et al. (2011) — Pinealon suppresses free-radical levels
The firmest direct evidence: synthetic Pinealon (Glu-Asp-Arg) showed dose-dependent restriction of ROS accumulation in cerebellar granule cells, neutrophils, and PC12 cells under oxidative stress, decreased propidium-iodide necrotic death, and a delayed ERK1/2 activation time-course with cell-cycle modification. Still a cell-level result — not human pharmacology.
EDR peptide & gene-expression regulation in AD (2020)
A Molecules review framing EDR/Pinealon as a peptide that may regulate gene expression and protein synthesis relevant to Alzheimer's-pathway biology, proposing peptide–DNA/chromatin interactions. A mechanistic hypothesis from the originating group — striking but unreplicated in independent labs, and explicitly noting EDR is a fragment isolated from Cortexin.
Arutjunyan et al. (2012) — Pinealon protects rat offspring
In a rat prenatal-hyperhomocysteinemia model (maternal methionine loading), Pinealon improved offspring cognitive function and made cerebellar neurons more resistant to oxidative stress — a clean animal neuroprotection signal that explicitly does not transfer to human pregnancy or pediatric use.
An aged-rat hypoxia/hypothermia stress model reported behavioral and neurochemical effects — and notably found Cortexin (the parent complex) stronger than Pinealon on free-radical processes and caspase-3, a useful honesty note that the isolated tripeptide isn't necessarily superior to its source.
Tripeptides & dendritic spines in an AD model (2021)
A Pharmaceuticals study/review on tripeptide neuroprotection reporting EDR/KED effects on dendritic-spine preservation in amyloid synaptotoxicity and 5xFAD-related models, proposing neuroepigenetic mechanisms — preclinical and hypothesis-heavy, not a human AD therapy.
Meshchaninov et al. (2015) — synthetic peptides & aging
The only indexed human study: oral synthetic peptides (Pinealon/Vesugen) in ~32 patients (aged 41–83) with chronic polymorbidity and organic brain syndrome in remission, reporting effects on biological-age and CNS indicators — low-certainty, not approval-grade, with Vesugen reported stronger than Pinealon.
Ilina et al. (2022) — neuroepigenetics of ultrashort peptides
A review of ultrashort peptides in Alzheimer's disease highlighting proposed epigenetic mechanisms and dendritic-spine findings across the EDR/KED family — useful for the mechanistic landscape, but a review that aggregates largely single-program preclinical work.
AEDG (Epitalon) gene-expression in neurogenesis (2020)
A sibling-peptide paper on AEDG/Epitalon stimulating gene expression and protein synthesis during neurogenesis via a proposed epigenetic mechanism — included to contextualize the bioregulator family whose pineal/thymus preparations have been studied in human gerontology, while keeping Pinealon and Epitalon mechanistically distinct.
FDA's broader peptide-compounding discussions emphasize that many peptides have not been adequately tested in humans and may pose risks; Pinealon itself was not clearly named in the Category 2 list reviewed, and as a tissue-extract-derived bioregulator it has no recognized US compounding pathway per FDA compounding-risk guidance. The regulatory backdrop for treating it as experimental.
GRADE summary — Overall evidence strength is low. Pinealon has a coherent preclinical story around oxidative stress, neuroplasticity, dendritic-spine preservation, and gene-expression hypotheses (Grade P for in-vitro, Grade C for animal), but the human evidence is sparse — one small low-certainty gerontology study plus open-label case series (Grade D) — and nearly all of it originates from a single research program with limited independent Western replication. There is no human PK, no dose-ranging, no randomized placebo-controlled trial, no approved indication, and no validated dose; there is no Grade A or B source. The biggest missing pieces are human pharmacokinetics, dose-finding, randomized controlled trials, long-term safety, and independent replication. Positioning: "an experimental neuroprotective tripeptide / EDR bioregulator with a real preclinical oxidative-stress and neuroplasticity signal but no approved dose and thin, single-program human evidence."
07 · Compare & contrast
Pinealon among the short neuro-peptides.
Pinealon sits in a cluster of short Russian-origin neuro-active peptides that are widely used in practice but share a common limitation: regional/practice evidence that hasn't met Western approval standards. The useful contrasts: Epitalon is the closest sibling (same bioregulator family, but pineal/telomerase-focused); Semax and Selank are mechanistically different neuropeptides (ACTH-fragment and tuftsin-analog respectively) with their own intranasal practice identities. The table keeps a single honest column constant — none is FDA-approved, and all rest on limited Western RCT evidence.
L1 · Consumer — Pinealon is a tiny three-amino-acid research peptide studied mostly for brain-cell protection, oxidative stress, and cognitive-aging support. The evidence is early and experimental, so it should not be treated as an approved memory, Alzheimer's, longevity, or sleep treatment.
L2 · Clinical — Pinealon / EDR is a synthetic tripeptide bioregulator with preclinical data suggesting ROS suppression, altered ERK1/2 timing, anti-necrotic effects, and possible neuroplasticity support in amyloid and metabolic-stress models. Human data are limited to small, low-certainty gerontology literature, with no validated PK, no approved indication, and no standardized dose.
L3 · Research — EDR is an ultrashort acidic/arginine-containing peptide proposed to act through antioxidant-response modulation, ERK/MAPK timing shifts, cell-cycle effects, peptide–genome/gene-expression interactions, and dendritic-spine preservation under amyloid synaptotoxicity. Translational confidence remains low because most claims are in-vitro, animal, or review-derived from a single program, and human dose-response/PK data are absent.
08 · References & evidence
Source register.
Evidence grades reflect the strength of support for the specific claim cited, not the prestige of the journal. For Pinealon the honest pattern is unusual: there is no Grade-A or Grade-B source at all. The firmest material is in-vitro mechanistic work (Grade P) and animal studies (Grade C); the single human study and the regulatory/identity records are Grade D. Several entries are reviews from the originating program, which is a confidence limitation worth keeping in view. The grade distribution is meant to make the thin, preclinical-dominant, single-program nature of the evidence visible at a glance.